Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $644 | $644 | $643 | $640 |
| - Cash | $1,270 | $4,278 | $11,609 | $1,041 |
| + Debt | $299 | $75 | $145 | $136 |
| Enterprise Value | -$327 | -$3,560 | -$10,821 | -$265 |
| Revenue | $448 | $1,493 | $19,375 | $511 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Gross Profit | $267 | $808 | $18,303 | $443 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| EBITDA | -$6 | $183 | $17,653 | $222 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |
| Net Income | -$100 | $114 | $8,467 | $110 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| % Growth | -206% | -98.7% | 7,556.7% | – |
| Operating Cash Flow | $104 | -$771 | $15,353 | $479 |
| Capital Expenditures | -$146 | -$403 | -$720 | -$128 |
| Free Cash Flow | -$42 | -$1,174 | $14,633 | $352 |